Follow-up data from a trial of 409 patients with non-Hodgkin’s lymphoma shows that treatment with Zevalin is long lasting, said the drug’s marketer, Seattle-based Cell Therapeutics (NASDAQ: [[ticker:CTIC]]). Researchers found that patients who had their tumors completely wiped out after taking Zevalin remained in remission for at least 67 months, compared with 31 months for patients in a control group, the company said today in a statement at the American Society of Hematology meeting in San Francisco. Cell Therapeutics recently signed a partnership with Spectrum Pharmaceuticals to co-market the drug, and is seeking permission from the FDA to sell it to a broader group of lymphoma patients.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
